Successful drug development hinges on multimillion-dollar decisions about mechanism of action, safety, dosage, and patient response. While genomics, transcriptomics, and proteomics are well-established tools in the drug development arsenal, these tools stop short of providing a real-time, definitive representation of the clinical phenotype.  

Join Derek Solum, Ph.D., Associate Director, Product Development at United Therapeutics, and Brian Keppler, Ph.D., Director, Discovery and Translational Sciences, Metabolon, Inc., as they share how metabolomics helped United Therapeutics enhance its multi-omics platform and improve decision-making across all phases of drug development.  

In this talk you’ll learn:

  • How United Therapeutics incorporates metabolomics into multi-omics workflow across pre-clinical, first-in-human, and late-stage clinical trials.
  • How the broad-scale use of targeted and untargeted metabolomics has helped researchers increase confidence in translatability of animal models, provide a clearer explanation of a drug’s mechanism of action, and provide direct evidence of phenotypic response for in vivo confirmation of genomic, RNA-seq, and protein data.
  • How metabolomics helped inform rapid decision-making in a pivotal Phase III study that made it possible to enhance product labeling based on the outcome of the study. 

Featured Speaker

Brian R. Keppler, Ph.D.

Director, Discovery and Translational Sciences
Metabolon, Inc.

Dr. Brian Keppler leads the team that collaborates with Metabolon’s Pharma, Biotech, and Applied Markets clients to illuminate novel biological insights and support meaningful decision-making to accelerate research and development and advance client success.  Brian has been with Metabolon since 2011 and contributes to Metabolon’s Business Development efforts as a scientific liaison for deep strategic partnerships. He received his Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill.

Derek Solum

Associate Director of Product Development
United Therapeutics

Derek Solum is the Associate Director of Product Development at United Therapeutics, a biotechnology company focused on the creation and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.  At United Therapeutics, Derek leads the Precision Medicine Initiative and supports clinical development strategy and implementation at all stages, from contracting/outsourcing to study start up and study conduct, execution, and close out.  Derek leads and manages large, global, multicenter clinical studies, prepares late stage clinical study protocols and study reports, and provides due diligence support for new expansion activities.


Register now for this webinar